Celgene

February 4, 2019

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment

August 31, 2017
The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

The CAR-T Revolution: Gilead’s $12B Acquisition of Kite Pharma & FDA Approval of Novartis’ Kymriah Signal Tipping Point for Promising Cancer Immunotherapies

August 23, 2016
Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?

Pfizer to Buy Medivation for $14 Billion, But Who Are the Real Winners?

Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation […]
June 27, 2016
Will Mesoblast recover from Teva & Celgene setbacks?

Will Mesoblast recover from Teva & Celgene setbacks?

Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, […]
July 1, 2015
Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies

Celgene & Juno Therapeutics announce landmark deal for CAR-T Cancer Therapies

Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will […]
Contact Us